Mario Gabelli Longeveron Inc. Transaction History

Gamco Investors, Inc. Et Al

  • $9.22 Billion
  • Q1 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022
SELL
$5.93 - $15.61 $192,725 - $507,325
-32,500 Closed
0 $0
Q1 2022

May 13, 2022
BUY
$5.06 - $13.8 $164,450 - $448,500
32,500 New
32,500 $449,000

About Longeveron Inc.

LGVN Quotes by TradingView
  • Ticker LGVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 5,925,940
  • Market Cap $9.54M
  • Description
  • Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult ...
More about LGVN
Track Mario Gabelli's Portfolio

Track Mario Gabelli Portfolio

Follow Mario Gabelli (Gamco Investors, Inc. Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gamco Investors, Inc. Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Gamco Investors, Inc. Et Al and Mario Gabelli with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email